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Abstract 
Background: Captopril and darbepoetin are drugs with high radio protective potential. 
Materials and Methods: The experiments were performed on male 55 Wistar rats. Rats were divided into 5 equal groups: 
1) Intact; 2) Control; 3) Captopril (15 mg/kg); 4) Darbepoetin alfa (5000 U/kg); 5) Captopril (15 mg/kg) + Darbepoetin alfa
(5000 U/kg). To simulate the RIED animals were subjected to ionizing-radiation injury at 500 roentgens with an exposure 
of 20 seconds. To evaluate the endothelial dysfunction (ED) level all rats were subjected to coefficient of ED (CED) 
calculation and determination of blood pressure (BP) and eNOS expression level, as well as diameter of cardiomycytes and 
carotid intima/media ratio. 
Results and Discussion: According to the degree of therapeutic effect, the used treatment schemes can be arranged in the 
following sequence (to reduce the effect): Captopril + Darbepoetin alfa > Captopril > Darbepoetin alfa. In this case, the 
combination of captopril 15 mg/kg i.p. + darbepoetin-alpha in a dose of 5000 U/kg i.p. brought the values of functional and 
laboratory tests to a group of intact animals. 
Conclusion: The combination of captopril + darbepoetin alfa has a high radio- and endothelioprotective potential and can 
be recommended for further preclinical and clinical studies. 
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Background 
The impact of radiation on biological systems 
continues to be one of the priority tasks of researches 
in modern biomedicine. Workers in nuclear power 
plants, nuclear submarines, cosmonauts, and many 
other professions face the risk of exposure to ionizing 
radiation. Patients at cancer clinics who have 
undergone radiation therapy are at high-increased risk 
for radiation-associated pathologies [1]. An important 
event of the last decades in radiobiology is the 
discovery of the contribution of radiation to the 
formation of cardiovascular pathology. In particular, a 
number of experimental and clinical observations 
demonstrate the contribution of radiation to the 
occurrence of endothelial dysfunction, arterial 
hypertension, dyslipidemia, and vascular wall 
remodeling and blood coagulation disorders [1, 2]. In 
spite of this, there is a certain gulf between the 
existing arsenal of pharmacological compounds, 
theoretically capable of reducing radiation-induced 
endothelial dysfunction (RIED) and the number of 
targeted preclinical trials. For example, angiotensin-
converting enzyme (ACE) inhibitors [3], 
erythropoietin preparations [4-7, 28-30], arginase 
inhibitors [8, 9], antioxidants [10, 11], NO donators 
[10, 11], statins [12-16, 24, 25] and some other drugs 
[19-21, 26, 27] are shown as agents capable of 
blocking important for RIED pathogenetic cascades. 
Materials and Methods 
Bioethics 
The experiments were carried out in compliance 
with the requirements of the federal law of the 
Russian Federation On Protection of Animals against 
Cruel Treatment dated June 24, 1998, the rules of 
laboratory practice in preclinical studies in the 
Russian Federation (GOST 3 51000.3-96 and GOST 
R 53434-2009), European Community directives 
(86/609 EU), the rules and the International 
Recommendations of the European Convention for 
the Protection of Vertebrate Animals used in 
experimental studies (1997) and the Laboratory 
Practice Rules adopted in the Russian Federation 
(order of the Ministry of Healthcare of the Russian 
Federation No. 708 of August 29, 2010). 
Animals and Groups 
The experiments were performed on male 55 
Wistar rats (245-275 g). The animals were kept in a 
standard conventional vivarium in individually 
ventilated cages (Techniplast, USA). Each animal was 
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subject to handling procedure 3 days before the 
experiment.12 hours before the experiment, animals 
were deprived of access to feed. 
Rats were divided into 5 equal groups: 
• Intact – Vehicle (NaCl 0,9%) 1 ml/kg 
intraperitoneally 1 time per day for 7 days 
• RIED – Radiation + L-NAME+ Vehicle (NaCl 
0,9%) 1 ml/kg intraperitoneally 1 time per day 
for 7 days 
• Captropril – Radiation + L-NAME+ Captopril 
12.5 mg/kg intraperitoneally 1 time per day for 
7 days 
• Darbepoetin alfa – Radiation + L-NAME + 
Darbepoetin alfa 5000 U/kg intraperitoneally 1 
time per 2 day for 6 days (3 times) 
• Captropril + Darbepoetin alfa - Radiation + L-
NAME + Captopril 12.5 mg/kg 
intraperitoneally 1 time per day for 7 days + 
Darbepoetin alfa 5000 U/kg intraperitoneally 1 
time per 2 day for 6 days (3 times) 
Pathology Modeling 
To simulate the RIED animals were subjected to 
ionizing-radiation injury at 500 roentgens with an 
exposure of 20 seconds LD=50/30 once (ROKUS-M, 
Russia). To gain the level of ED due enhancement of 
nitric oxide deficiency and vascular wall injury we 
also injected L-NAME daily for 7 days once a day, 
intraperitoneally, at a dose of 15 mg/kg. 
Endothelial dysfunction evaluation 
All animals were subject to coefficient of 
endothelial dysfunction (CED) evaluation as 
described previously [22]. In brief, the common 
carotid artery was cathetized and connected to a 
pressure transducer (Biopac Systems, USA). Then a 
solution of acetylcholine at a dose of 40 µg/kg 
(endothelium-dependent vasodilation) and a solution 
of sodium nitroprusside at a dose of 30 µg/kg 
(endothelium-dependent vasodilatation) were injected 
into the femoral vein. The area under curve (AUC) of 
the pressure drop in response to nitroprusside divided 
by the AUC of pressure drop in response to 
acetylcholine was taken as CED. 
Histology 
After CED evaluating, the animals were 
euthanized by cardiac puncture under anesthesia. The 
heart, carotid arteries, abdominal aorta, and renal 
arteries were excised, fixed in 10% buffered formalin, 
stained in hematoxylin-eosin the intima/media for 
morphometrically evaluation of intima/media ratio 
and cardiomyocytes diameter. 
Western-blot 
The level of eNOS expression in abdominal aorta 
was determined in a cell lysate as previously 
described [23]. After the incubation, cell were washed 
three times with 5 mM phosphate buffer. The cells 
from one well were collected in 100 μl of lysis buffer, 
centrifuged for 10 min at 1000 g and subjected to 
polyacrylamide gel electrophoresis. Each plate was 
applied a mixture of pre-stained protein markers with 
a molecular weight range (Mm) 7000-200000 Yes 
(Bio-Rad Kaleidoscope Prestained Standards, USA). 
At the end of electrophoresis, the proteins were 
transferred from the gel to a nitrocellulose membrane 
— Western blot (60 V, 1 hour). After washing the 
membrane three times with 5_mM phosphate buffer 
pH 7.4, containing 150 mM NaCl and 0.05% Tween-
200, it was treated overnight with a solution of 
polyclonal rabbit antibodies against human eNOS 
(BD Transduction Labs, USA) diluted (ratio=1:500). 
Then the membrane was washed and incubated for an 
hour with diluted at a ratio of 1:300 secondary 
antibodies conjugated with horseradish peroxidase 
(goat anti-rabbit IgG antibodies, Sigma, USA). The 
strip corresponding to eNOS was detected according 
to its molecular weight, as compared with the tap 
proteins. The film was dried in air, the strips were 
scanned and the area under the curve was calculated 
using the Total Lab program. 
Statistical assay 
The data was checked for normal distribution. The 
type of distribution was determined by the criterion of 
Shapiro-Wilk. In the case of a normal distribution, the 
mean value (M) and standard error of the mean (m) 
were calculated. In cases of non-parametric 
distribution, the median (Me) and quartile range (QR) 
were calculated. Intergroup differences were analyzed 
by MANOVA with post-hoc analysis or Mann-
Whitney with Bonferroni correction test, depending 
on the type of distribution. Statistical analysis was 
performed using Statistic a 10.0 software. 
Results and Discussion 
Immediately after irradiation and for the next 7 
days, the animals showed no significant changes in 
behavior and phenotype, except for a slight anxiety. 
Irradiation followed by the introduction of L-NAME 
led to the development of persistent hypertension, 
accompanied by an increase in systolic blood pressure 
to 181.2 ± 2.5 mm Hg. Art. (in contrast with 
115.3±1.9 in intact group). When studying the 
functional and laboratory signs of endothelial 
dysfunction, an increase in CCED was observed from 
1.15±0.09 to 5.75±0.10 c.u. (Fig 1.A), intima / media 
ratio from 0.22±0.01 to 0.31±0.02 c.u. (Fig 1.B) and a 
decrease in eNOS expression from 6.11±0.07 to 
2.12±0.08% (Fig 1.C). At the same time, there was an 
increase in the diameter of myocardiocytes from 
8.7±0.1 to 13.5±0.2 µm (Fig 1.D), which can be 
Journal of International Pharmaceutical Research, ISSN: 1674-0440 292 
 
 
explained as a result of a deficit of nitric oxide and an increase in the afterload on the heart. 
 
Figure -1: Impact of RIED modeling on the CED (A), Intima/Media ratio (B), eNOS expression (C) and 
diameter of cardiomyocytes (D, E). 
Captopril darbepoetin and their combination 
improved functional and laboratory parameters, 
reducing CED (Table 1), the intima/media ratio and 
the diameter of cardiomyocytes, as well as increasing 
the expression of eNOS in comparison with the non-
treated group. At the same time, according to the 
degree of therapeutic effect, used treatment schemes 
can be arranged in the following sequence (to reduce 
the effect): Captopril + Darbepoetin alfa > Captopril > 
Darbepoetin alfa. 
Table -1: Impact of captopril, darbepoetin and combined therapy on the functional and laboratory 
parameters of rats with RIED. 
Group Systolic BP, 
mmHg 






Intact 115.3±1.9 1.15±0.08 0.22±0.01 6.11±0.07 8.7±0.1 
RIED 181.2±2.5 5.75±0.10 0.31±0.02 2.12±0.08 13.5±0.2 
Captopril 129.1±1.5* 2.69±0.09* 0.27±0.01* 3.11±0.08* 10.5±0.2* 





0.24±0.01* 5.99±0.08* y 9.0±0.2* y 
Note: BP – Blood pressure; * - p<0,05 in comparison with RIED group; y - p<0,05 in comparison with 
Captopril group 
As can be seen from table 1, captopril significantly 
improved all measurable indicators, while darbepoetin 
alpha monotherapy did not affect the intima/media 
ratio, systolic pressure and diameter of 
cardiomyocytes. 
The combination of captopril and darbepoetin 
showed the most pronounced effect, significantly 
reducing CED, eNOS expression and diameter of 
cardiomyocytes in comparison with captopril 
monotherapy (Table 1). 
It is possible to associate the obtained effect with 
the fact that the therapeutic contribution of captopril is 
realized through a combination of its own 
radioprotective effect and hypotensive action. Perhaps 
darbepoetin alpha has a high endothelioprotective 
activity on this model, which was shown to be a 
significant decrease in СED, but did not show a 
sufficient therapeutic effect due to the fact that it is 
not able to reduce blood pressure. 
In the case of a combination of two drugs, the 
radioprotective and antihypertensive effects of 
captopril add to the anti-apoptotic effect of 
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darbepoetin and protect the endothelium to a very 
high degree. 
Conclusions 
1. Simulation of RIED by irradiation of male rats 
500 R results in the development of severe 
hypertension and endothelial dysfunction, confirmed 
by functional and laboratory tests. 
2. Captopril at a dose of 15 mg/kg i.p. significantly 
improves the functional and morphological state of 
the vascular wall, and also prevents the development 
of cardiomyocyte hypertrophy. 
3. Darbepoetin-alpha monotherapy at a dose of 
5000 U/kg has a weak and selective therapeutic effect 
on the RIED expert model. 
4. The combination of captopril 15 mg/kg i.p. + 
darbepoetin-alpha in a dose of 5000 U/kg i.p. It has a 
strong radio and endothelioprotective effect, bringing 
the values of functional and laboratory tests to a group 
of intact animals. 
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